Loading...
01/10 16:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Strong points include the launch of Eversense 365, increased net revenue, and improved gross profit. However, concerns about regulatory issues, supply chain challenges, and competitive pressures balance these positives. The Q&A section reveals uncertainties about partnerships and integration timelines, further tempering optimism. Financial health is stable, but the lack of clear guidance and ongoing risks suggest a neutral outlook for the stock price over the next two weeks.
Net Revenue $6.3 million, up 24% from $5 million in the prior year period.
U.S. Revenue $4.5 million, part of the total net revenue.
International Revenue $1.8 million, part of the total net revenue.
Gross Profit $1.5 million, up from $0.3 million in the prior year period, primarily driven by increased margins on the 365-day product and a positive impact of $0.4 million in manufacturing costs previously expensed to R&D.
Gross Profit Margin Approximately 18%, improved due to increased margins on the 365-day product despite seasonality effects reducing ASPs.
Research and Development Expenses $7.3 million, down $3.1 million from the prior year due to reduced clinical study spend and consultant costs.
Selling, General and Administrative Expenses $7.7 million, down $0.4 million from $8.1 million in the prior year, primarily due to favorable personnel costs, consulting fees, and legal expenses.
Net Loss $14.3 million, or $0.02 loss per share, improved from a net loss of $18.9 million, or $0.03 loss per share in the prior year, due to improved gross profit margins and reduced R&D costs.
Cash and Cash Equivalents $64.6 million as of March 31, 2025.
Debt and Accrued Interest $35.3 million, reduced from $55.7 million after repaying $20.4 million in convertible notes.
Common Stock Issuance Proceeds Approximately $27 million from the sale of common stock, expected to extend cash runway into mid-2026.
Eversense 365 Integration: Integration with Sequel’s twiist Automated Insulin Delivery System for real-time glucose monitoring and insulin delivery adjustments.
Eversense 365 Launch: Expected European launch in the second half of 2025 following CE Mark approval.
Gemini Product Development: Pivotal study IDE submission planned by year-end for Gemini, featuring a one-year sensor with built-in battery.
Freedom System Development: Development of the Freedom system, an invisible CGM that communicates directly with the user's phone.
European Market Expansion: CE Mark application filed for Eversense 365, with a planned launch in Europe in the second half of 2025.
U.S. Market Expansion: Transitioning reimbursement from 180 to 365 days for Eversense, with many payers already covering the full year.
Revenue Growth: Q1 2025 net revenue grew 24% to $6.3 million compared to $5 million in Q1 2024.
Cost Management: Gross profit increased to $1.5 million due to improved margins on Eversense 365.
Partnerships: Collaboration with SweetSpot for virtual CGM monitoring to enhance patient care.
Health System Integration: Ongoing discussions with health systems to include Eversense 365 in standard offerings.
Regulatory Issues: The company is awaiting CE Mark approval for the Eversense 365, which is critical for the planned European launch in the second half of 2025.
Supply Chain Challenges: The company is monitoring the evolving tariff situation, which could impact gross profit margins. They have a global supply chain and utilize contract manufacturers, with a small percentage of components sourced from China.
Competitive Pressures: The integration of Eversense 365 with Sequel’s twiist Automated Insulin Delivery System is a strategic move to enhance competitiveness in the diabetes care market.
Economic Factors: The company anticipates a steady increase in patient numbers and revenue, but acknowledges potential impacts from tariffs and the need for effective expense management.
Partnership Risks: The restructuring at Mercy Health Systems has paused ongoing initiatives, which could delay the integration of Eversense with remote patient monitoring.
Eversense 365 Integration: Integration with Sequel’s twiist Automated Insulin Delivery System to enhance diabetes management.
Collaboration with SweetSpot: Enables virtual CGM monitoring for endocrinology practices, improving patient care and efficiency.
European Launch: Anticipated launch of Eversense 365 in the second half of 2025 following CE Mark approval.
Pipeline Products: Development of Gemini and Freedom systems to enhance patient experience and monitoring capabilities.
2025 Revenue Guidance: Expected global net revenue of approximately $34 million to $38 million.
Gross Profit Margin: Projected gross margins between 25% and 30% for the full year 2025.
Patient Base Growth: Expecting to double the global patient base in 2025 compared to 2024.
Cash Utilization: Projected cash utilization between $50 million and $60 million in 2025.
Common Stock Sale Proceeds: In Q1, we received gross proceeds of approximately $27 million from the sale of common stock, by utilizing our at-the-market facility.
Debt Repayment: In January, the remaining outstanding 2025 convertible notes in the principal amount of $20.4 million were repaid, reducing the total principal debt outstanding to $35 million.
Preferred Stock Conversion: All preferred stock was converted into shares of common stock, with 12,000 shares of Series B preferred stock converted into about 30.4 million shares of common stock.
The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
The earnings call shows strong financial performance with a 37% increase in net revenue and improved gross profit margins. Despite a net loss, the company reduced R&D expenses and increased cash position through public offerings. The Q&A section highlights positive retention rates and potential growth from the consignment program and Eon Care. However, there are uncertainties in retention data for the 365 version and revenue impact from Eon Care. Overall, the financial results and strategic initiatives suggest a positive stock price movement in the short term.
The earnings call presents mixed signals. Strong points include the launch of Eversense 365, increased net revenue, and improved gross profit. However, concerns about regulatory issues, supply chain challenges, and competitive pressures balance these positives. The Q&A section reveals uncertainties about partnerships and integration timelines, further tempering optimism. Financial health is stable, but the lack of clear guidance and ongoing risks suggest a neutral outlook for the stock price over the next two weeks.
The earnings call presents a mixed outlook. Positive aspects include a 24% increase in net revenue and improved gross profit margins, alongside optimistic guidance for 2025. However, risks such as potential delays in CE Mark approval, competitive pressures, and partnership uncertainties with Mercy Health temper the overall sentiment. The Q&A reveals a lack of clarity on certain strategic integrations and commercial plans, adding to uncertainty. Given these factors, the stock is likely to experience a neutral movement in the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
